Theralase Technologies Inc (TLTFF)

[123414]

Strong PH1 NMIBC Completed trial results commanded attention.

More attention for this tiny independent company will be coming.

Incredible science and cutting edge technology.

Much in the pipeline that analyst Loe did not even factor into his rating.

peculative Buy $0.90 Target
Target initiated 5 September 2017
Speculative Buy rating to the firm, with a one-year PT of $0.90.

But for now, TLD-1433’s contribution to our revenue/EBITDA forecasts is solely driven by our royalty revenue projections in BCG-refractory NMIBC only.
(The company has already began work with brain and lung cancers as well as others.)

We describe TLD-1433 clinical timelines embedded in our financial forecasts that we derive below, but as a key takeaway, we believe that TLD-1433 could be FDA-approved and launched by FH222 under best-base scenario, assuming that pivotal US testing begins by FH219 and that one-year recurrence free survival (RFS) data are available by FH122. (pg 1)

Bladder cancer-targeted PDT TLD-1433 is a major value driver in our model
http://67.212.93.22/research/content/20170905TLT%20final.pdf
**********************************************************************
**********************************************************************
Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
https://www.fscwire.com/newsrelease/theralase-successfully-completes-phase-ib-non-muscle-invasive-bladder-cancer-clinical
**********************************************************************

The Company is planning to meet with Health Canada and FDA, to discuss and finalize the design of a Health Canada and FDA pivotal Phase II NMIBC clinical study, with a primary endpoint of efficacy.
https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=6776145775401349&topic=TLTFF&symbology=null&cp=null&webmasterId=90338
**********************************************************************


________________________________________________________________________


We are on track to meet or modestly exceed the analysts expectations by the timely completed phase 1 study and the Phase 2 study on track for annalists expectations.

Further, please note the supportive warrant and options that have proven very supportive of the company's finances in the past year.

Warrants and option outstanding.
Current outstanding shares- 131,585,526
5,104,000 warrants at 30 cents
14,236,666 warrants at 38 cents
18,181,817 warrants at 54 cents
10,310,000 options at 50 cents
fully diluted 179,418,009

Combined would bring in almost $22 million CAD. Probably enough to fund Ph2. Like I mentioned earlier we should already by around $6 considering there won't be a Ph3. There shouldn't be anymore dilution imo.

http://www.stockhouse.com/companies/bullboard?symbol=v.tlt&postid=28101154

Theralase Sustains IP Strength with Newly Issued US Patents Since our Original Report, with TLD-1433 Well Patented Until at Least 2033

But for now, TLD-1433’s contribution to our revenue/EBITDA forecasts is solely driven by our royalty revenue projections in BCG-refractory NMIBC only.

http://67.212.93.22/research/content/20170905TLT%20final.pdf



So what if they hit the mark of Doug Loe's target and then we get a new target price even stronger?


This stock may rise on lower volume for a bit.

Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=5662509633998797&topic=TLTFF&symbology=null&cp=null&webmasterId=90338

Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours


Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, intended to safely and effectively destroy cancer, has announced significant benefits of its Rutherrin® (TLD-1433 + transferrin) formulation in comparison to a clinically approved PDC Amino Levulinic Acid (“ALA”), in the destruction of Rat Glioma (“RG2”) brain tumours, representative of GlioBlastoma Multiforme (“GBM”), a deadly form of human brain cancer.

As previously disclosed, Theralase demonstrated that rats subjected to RG2 cancer cells, developed brain tumours representative of GBM. After intravenous (“IV”) injection of Rutherrin® and subsequent laser light activation, these animals survived significantly longer that animals who did not receive treatment and/or were treated with ALA-PDT.

Further research conducted by Theralase researchers has demonstrated that Rutherrin® is able to provide a significant (up to 400 %) improvement in survival in animals treated with Rutherrin® versus IV injection of ALA and subsequent laser light activation. (Figure 1)

Figure 1. Animal Survival Analysis (Kaplan-Meir)

To view the graphic in its original size, please click here

Magnetic Resonance Imaging (“MRI”) data obtained from the pre-clinical experiments show that in the animals treated with Rutherrin® there was less non-specific inflammation in the brain as compared to ALA treated animals.

This observation is considered clinically advantageous; as excessive inflammation of brain tissue is known to cause post-treatment clinical complications, such as: lethal damage to brain tissue (cerebral death), bleeding in the brain and/or stroke due to increased intracranial pressure through the brain’s confinement in the skull. (Figure 2)
https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=7665778968088651&topic=TLTFF&symbology=null&cp=null&webmasterId=90338